Galectin Therapeutics
Open
$2.27
Prev. Close
$2.27
High
$2.27
Low
$2.26
Market Snapshot
$145.06M
-4.7
-0.76
15
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
emptyResult
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Recently from Cashu
Galectin Therapeutics: Key Developments and Future Prospects in Biotechnology.
Please provide the text you would like summarized, and I will be happy to help!
Galectin Therapeutics: Key Developments and Insights into Stock Performance
Sure, please provide the text you would like me to summarize.
Request for Content to Summarize on Galectin Therapeutics
I apologize, but it seems that there is no content provided for me to summarize regarding Galectin Therapeutics or its industry. Please share the relevant content, and I will gladly assist you in crea…
Galectin Therapeutics: Summary of Key Developments and Insights
I apologize, but it seems that you haven't provided the text that you would like summarized. Could you please share the content you want me to work on?